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ABSTRACT: The α7 nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel widely distributed in the central
nervous system, mainly in the hippocampus and cortex. The enhancement of its activity by positive allosteric modulators (PAMs) is
a promising therapeutic strategy for cognitive deficits and neurodegenerative disorders. With the aim of developing novel scaffolds
with PAM activity, we designed and synthesized a series of phosphonate-functionalized 1,4-disubstituted 1,2,3-triazoles using
supported copper nanoparticles as the cycloaddition reaction catalyst and evaluated their activity on α7 receptors by single-channel
and whole-cell recordings. We identified several triazole derivatives that displayed PAM activity, with the compound functionalized
with the methyl phosphonate group being the most efficacious one. At the macroscopic level, α7 potentiation was evidenced as an
increase of the maximal currents elicited by acetylcholine with minimal effects on desensitization, recapitulating the actions of type I
PAMs. At the single-channel level, the active compounds did not affect channel amplitude but significantly increased the duration of
channel openings and activation episodes. By using chimeric and mutant α7 receptors, we demonstrated that the new α7 PAMs
share transmembrane structural determinants of potentiation with other chemically nonrelated PAMs. To gain further insight into
the chemical basis of potentiation, we applied structure−activity relationship strategies involving modification of the chain length,
inversion of substituent positions in the triazole ring, and changes in the aromatic nucleus. Our findings revealed that the
phosphonate-functionalized 1,4-disubstituted 1,2,3-triazole is a novel pharmacophore for the development of therapeutic agents for
neurological and neurodegenerative disorders associated with cholinergic dysfunction.
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■ INTRODUCTION
The α7 receptor is one of the major nicotinic acetylcholine
receptors (nAChRs) in the central nervous system, particularly
present in the hippocampus, cortex, and subcortical limbic
regions. It is involved in the modulation of neural circuits
associated with cognition, memory, learning, attention, and
sensory gating information.1,2 Also, α7 is expressed in many
non-neuronal cells, where it plays a role in immunity,
inflammation, and neuroprotection.3,4
α7 is a pentameric ligand-gated ion channel (pLGIC) that
contains an extracellular domain (ECD), which carries the
agonist binding sites at subunit interfaces, a transmembrane
domain (TMD), that forms the ion pore, and an intracellular
domain (ICD). Between ECD and TMD, there is a transition
zone, composed by several loops, that is essential to couple
agonist binding to channel gating.5 Binding of acetylcholine
(ACh) to the receptor triggers the opening of the ion channel
permeable to cations including calcium, which results in rapid
membrane depolarization and calcium influx into the cell.3,6
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This fast ionotropic response is further prolonged by signal
transduction pathways and the release of calcium from
intracellular stores due to the dual ionotropic/metabotropic
nature of α7.3,4
Decline in α7 activity has been associated with several
neurological, neurodegenerative, and inflammatory disorders,
such as Alzheimer’s disease and schizophrenia. The enhance-
ment of α7 function has, therefore, emerged as a therapeutic
strategy for these disorders.2,3,7 Positive allosteric modulators
(PAMs) are promising therapeutic tools, because they exhibit
several advantages over orthosteric agonists, which include the
conservation of the temporal and spatial pattern of the
endogenous activation by ACh, higher selectivity, fewer side
effects, and enormous structural diversity.3,8,9 Based on their
effects on macroscopic currents evoked by ACh, PAMs have
been classified as type I and type II. Both types of PAMs
enhance the agonist-elicited peak currents; however, whereas
type I PAMs exert minimal or no changes in desensitization,
type II PAMs decrease the desensitization rate and reactivate
receptors from desensitized states.3,8,10
Both types of PAMs exhibit a wide chemical and structural
diversity, ranging from small molecules to entire proteins.11
Their structures include aromatic rings; nitrogen-, oxygen-, and
sulfur-containing heterocycles; donors and acceptors of
hydrogen bonds; etc. Although this broad spectrum of
structures constitutes a disadvantage for identifying a lead
structure, it also brings the possibility to explore a wide range
of molecules and functional groups for improving potency,
efficacy, and selectivity during the development of novel
therapeutic compounds.
Among the several nitrogen-containing heterocycles present
in α7 PAMs (pyridines, isoxazoles, thiazoles, indoles, etc.),
triazoles have been explored only in a few studies as ligands for
nAChRs.12,13 However, they have shown a wide range of
pharmacological activities, including antimicrobial, analgesic,
anti-inflammatory, local anesthetic, anticonvulsant, antineo-
plastic, antimalarial, antiviral, antiproliferative, anticancer,
antimicotic, and antihistaminic activities.14,15 In particular,
1,4-disubstituted 1,2,3-triazoles have not been explored in the
design and development of α7 PAMs, even when the structure
has been used as a scaffold for several drugs in medicinal
chemistry, as it can be obtained in a regiospecific manner
through the copper(I)-catalyzed azide−alkyne cycloaddition
(CuAAC).14,16
With the aim of developing new synthetic PAMs, we
designed and synthesized a novel series of 1,4-dibustituted
1,2,3-triazoles using supported copper nanoparticles on
activated carbon (CuNPs/C) as the cycloaddition reaction
catalyst. This kind of catalyst is readily prepared under mild
conditions and exhibits a high versatility in the multi-
component click synthesis of 1,2,3-triazoles.17,18 We chose an
aryl group and a phosphonate group as substituents in
positions 1 and 4, respectively. The phosphonate group,
which is characterized by a stable carbon−phosphorus bond
(C−P), was selected because it is a bioactive functional group
which is poorly exploited and not explored in nAChRs to
date.19,20 However, it has a promising therapeutic potential for
several human health disorders and has been included in
antibiotics, herbicides, antivirals, glutamate receptor antago-
nists, anticancer and antiresorptive agents, acetylcholinesterase
(AChE) inhibitors, metal chelators, etc.19,20
The compounds showing functional activity were identified
through high-resolution single-channel, and macroscopic
current recordings of human α7, which allowed their potencies
and efficacies as well as the mechanisms and structural
determinants underlying potentiation of receptor function to
be determined. We also applied structure−activity relationship
(SAR) strategies to obtain derivatives by modifying the chain
length, inverting the substituent positions on the triazole ring,
and varying the aromatic nucleus. Our findings revealed that
the phosphonate-functionalized 1,4-disubstituted 1,2,3-triazole
is a key pharmacophore for the development of new potential
therapeutic agents.
■ RESULTS AND DISCUSSION
Design of Novel α7 Positive Allosteric Modulators
and Evaluation of Their Functional Activities. Because
potentiation of α7 is emerging as a promising therapeutic
Figure 1. Design of 1,4-disubstituted 1,2,3-triazoles as α7 PAMs. The moieties present in reported α7 PAMs were the naphthyl group of TQS (4-
(naphthalen-2-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide) and the hydroxymethyl group of JNJ-1930942 (2-[[4-fluoro-3-
(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol).
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strategy for the treatment of cognitive deficits, schizophrenia,
pain, and inflammatory processes, the synthesis of novel α7
ligands is of current relevance. This work combines synthetic
chemistry with electrophysiological recordings of human α7 to
generate novel ligands that modify receptor function and to
reveal their molecular mechanisms of action.
Given that the 1,2,3-triazole ring can act as bioisostere of
several nitrogen-containing heterocycles,21 in particular 1,2,4-
triazoles22 and isoxazoles23 that are present in some structures
of known α7 PAMs, we evaluated the potential of this scaffold
as a novel PAM for α7. We also included other moieties found
in reported α7 PAMs, the naphthyl group present in TQS10,
and the hydroxymethyl group present in JNJ-1930942,24 which
in turn, allowed us further functionalization into phosphonates
(Figure 1).
Synthesis of 1,4-Disubstituted 1,2,3-Triazole Series I. As
shown in Scheme 1, triazole 2 was obtained in high yield
(80%) from 1-(chloromethyl)naphthalene (1) and propargyl
alcohol, through the multicomponent CuAAC in water, using
CuNPs/C as the catalyst.18 Subsequently, compound 2 was
treated with CBr4 and PPh3 in dichloromethane (DCM) to
afford bromide 3 (80%). The Michaelis−Becker reaction on
compound 3 was performed with two different H-phospho-
nates, to give phosphonates 4a−b in good yields (70−76%).
Finally, dimethyl phosphonate 4a was subjected to hydrolysis
with trimethylsilyl bromide (TMSBr) in DCM to give the
corresponding phosphonic acid 5 (85%).
Pharmacological Activity of Triazole Derivatives Series I
on Human α7 Receptors. To evaluate the potential activity of
series I as modulators of human α7, we performed single-
channel recordings in the cell-attached patch configuration
from BOSC23 cells expressing the receptor. In these
experiments, the compounds were applied together with 100
μM ACh, which is close to the EC50 concentration for receptor
activation.3 Compounds were evaluated at the micromolar
range based on the active concentrations of α7 PAMs
previously described because this range is considered
promising for therapeutic use.25
For α7 receptors, single-channel activity induced by ACh
appeared mainly as brief and isolated openings shown as
upward deflections and flanked by long closed periods or, less
frequently, as activation episodes named bursts.25,26 Bursts
consist of a few opening events in quick succession, which are
evoked by a single receptor molecule25,26 (Figure 2). The
mean open and burst durations can be obtained from the
corresponding histograms as described in the Materials and
Methods (Figure 2).
α7 PAMs have been classified in two types according to their
effects on macroscopic currents evoked by ACh. However,
single-channel recordings are more sensitive to detecting
kinetic changes than macroscopic recordings. At the single-
channel level, potentiation of α7 by both types of PAMs is
detected by the increase in burst and open durations.3,27,28 The
impact of both types of PAMs on α7 kinetics covers a wide
spectrum of enhanced durations. Type II PAMs produce a
more profound potentiation, and in some cases, they can
increase the activation episodes from the sub-millisecond range
to the second range. Type I PAMs typically exert more modest
effects on the scale of several milliseconds, which, in turn,
make them more suitable and promising for therapeutic
use.3,25,29
To identify triazole derivatives with functional α7-PAM
activity, we measured single-channel currents in the presence
of ACh (100 μM) and each compound (50 μM). Open and
burst duration histograms of α7 in the absence of PAMs were
described by the sum of two exponential components. From
the corresponding histograms, we obtained the durations and
relative areas of the components in the absence or presence of
the compounds, and the average values are shown in Table 1.
The burst duration corresponds to the duration of the slowest
component of the corresponding histogram (see Materials and
Methods). Potentiation is typically detected as an increase in
burst and open durations. Additionally, an increase in the
relative area of the longest duration open component without
changes in its duration may underlie potentiation. However,
relative areas of components are usually more variable among
recordings, and the increase in the proportion of longer
opening events leads to a concomitant increase in burst
duration. Thus, in general, the efficacy of α7 PAMs can be
more accurately determined from their capability to increase,
primarily, burst duration and also open durations.3,28,29
Scheme 1. Synthesis of 1,4-Disubstituted 1,2,3-Triazole Series Ia
aReagents and conditions = (i) CuNPs/C (5 mol %), NaN3, H2O, 75 °C (82%); (ii) CBr4, PPh3, DCM, from 0 °C to rt (80%); (iiia) NaH,
HPO3R2, 0 °C and (iiib) 3, from 0 °C to rt (70−76%); and (iv) 4a, TMSBr, DCM, rt (85%).
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Compound 2 increased the duration of the brief open
component and induced a small increase in the mean burst
duration, indicating slight PAM activity (∼1.2 times with
respect to the control, Table 1, Figure 2). In contrast,
compound 3 did not exert any statistically significant effect on
the single-channel currents elicited by ACh (Table 1). Open
and burst duration histograms were fitted by two exponential
components for both conditions (Figure 2). The fact that
compounds 2 and 3 differ only in the presence of a hydroxyl or
a bromide group (Scheme 1) suggests that higher polarity is
required for the potentiating activity. Then, we evaluated the
two phosphonates, compounds 4a and 4b, and the phosphonic
acid 5 (Scheme 1).
Compound 4a carrying the methyl phosphonate group
exhibited a robust α7-PAM activity. Open and burst duration
histograms were fitted by three exponential components
instead of the two described for the control condition (Figure
2). The open time histograms showed that the first open
component diminished its area at the expense of an increase in
the area of the second component and that a novel long
duration component appeared (Table 1). Thus, potentiation
was evidenced by a statistically significant ∼4-fold increase in
the mean open duration (considering the longest duration
Figure 2. Effects of the 1,4-disubstituted 1,2,3-triazole series I on α7 receptors at the single-channel level. (Left) Typical traces of α7 channel
currents in the presence of 100 μM ACh alone or combined with each compound (50 μM). Channel openings are shown as upward deflections.
(Right) Representative open and burst duration histograms for each condition. Membrane potential = −70 mV. Filter = 9 kHz.
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component) and by an ∼7-fold increase in mean burst
duration, with respect to the control condition (Table 1,
Figure 2).
Compound 4b also exerted PAM activity but was less
efficacious than 4a. The histograms of open durations showed
the presence of a new component of longer duration and no
statistically significant differences in the durations and areas of
the other two open components with respect to the control
condition (Figure 2). The mean open duration (considering
the longest duration component) and the mean burst duration
increased ∼2.5 and ∼4.6 times, respectively (Table 1, Figure
2).
Compound 5, carrying the phosphonic acid group, produced
a slight potentiation, which was evidenced only as an increase
in the mean burst duration (Table 1, Figure 2). In this case, the
open and burst duration histograms were fitted by two and
three exponential components, respectively.
In order to examine the potentiation by phosphonates and
the phosphonic acid in more detail, we measured single-
channel currents elicited by 100 μM ACh together with the
synthetic compounds at a broader concentration range, from 5
to 150 μM (Table 2). For this analysis, we only considered the
burst duration and the duration of the slowest component of
the open time histogram (named as τopen in Table 2), because
as shown below, these were the parameters that better revealed
the potentiating effect.
We found that compound 4a was the most potent and
efficacious, exerting its potentiating effect from 10 to 100 μM
(Table 2). A slight potentiating effect was observed at 5 μM in
only two out of six recordings, which showed additional open
and burst components with increased durations (τopen ∼ 0.62
ms and τburst ∼ 0.86 ms). Potentiation by compound 4b was
evident at 10 μM as a slight increase (∼1.8 times) in the mean
burst duration (Table 2). However, its maximal positive
modulatory activity was observed at 50 μM (Table 2, Figure 2,
Figure S1). In the presence of compound 5, we detected, in
only two out of four recordings, a modest increase in the mean
burst duration at 5 μM (∼0.95 ms). The maximal potentiation
was achieved at 10 μM and was mainly observed as an increase
Table 1. Single-Channel Parameters of α7 Receptors in the Presence of Compounds Series Ia
series I τo1 (ms) τo2 (ms) τo3 (ms) τburst (ms) n N
(area) (area) (area)
0.07 ± 0.02 0.27 ± 0.03 0.32 ± 0.06 7 6
(0.90 ± 0.10) (0.10 ± 0.05)
2 50 μM 0.16 ± 0.03### 0.30 ± 0.04 0.42 ± 0.05** 7 3
(0.85 ± 0.06) (0.15 ± 0.06)
3 50 μM 0.09 ± 0.02 0.29 ± 0.07 0.34 ± 0.07 4 3
(0.77 ± 0.15) (0.23 ± 0.15)
4a 50 μM 0.09 ± 0.04 0.34 ± 0.07 1.06 ± 0.04*** 2.26 ± 0.34*** 4 3
(0.64 ± 0.09)## (0.33 ± 0.09)## (0.03 ± 0.01)
4b 50 μM 0.08 ± 0.01 0.30 ± 0.09 0.68 ± 0.12*** 1.46 ± 0.67*** 7 5
(0.82 ± 0.09) (0.17 ± 0.09) (0.01 ± 0.004)
5 50 μM 0.07 ± 0.01 0.25 ± 0.06 0.50 ± 0.10** 4 3
(0.87 ± 0.05) (0.13 ± 0.05)
aSingle-channel currents were recorded from cells expressing human α7 wild type activated by 100 μM ACh in the absence or presence of the
synthetic compounds shown in Scheme 1. τo1, τo2, and τo3 correspond to the time constants of the open components determined from fitting the
open time histograms. The relative area of each component is shown in brackets below its duration. The mean burst duration (τburst) corresponds
to the time constant of the slowest exponential component of the burst duration histogram. Values are mean ± SD. n = number of independent
experiments, each from different cell patches. N = number of cell transfections. Statistical analysis was conducted by one way ANOVA followed by
Bonferroni’s post hoc tests for multiple comparisons. The asterisk symbol (*) indicates statistical significance determined by comparing the mean
durations of the slowest components of open and burst duration histograms in the presence of each compound with respect to those in the absence
of compounds. The pound symbol (#) indicates statistically significant differences in duration or area among the same components between
experimental and control conditions. The number of symbols (one, two, or three) indicates different significant p-values independently of the type
of symbol (for instance, p < 0.05*, p < 0.01**, p < 0.001***).
Table 2. Single-Channel Properties of α7 in the Presence of




a τburst (ms) n N
0.27 ± 0.03 0.32 ± 0.06 7 6
4a 5 0.22 ± 0.06 0.27 ± 0.09 6 4
10 1.05 ± 0.02*** 2.08 ± 0.13*** 6 4
50 1.06 ± 0.04*** 2.26 ± 0.34*** 4 3
100 0.52 ± 0.01*** 0.96 ± 0.04*** 4 3
150 0.13 ± 0.02*** 0.25 ± 0.05 4 3
4b 5 0.36 ± 0.20 0.33 ± 0.08 4 3
10 0.32 ± 0.09 0.57 ± 0.06*** 5 3
50 0.68 ± 0.12*** 1.46 ± 0.67*** 7 5
100 0.20 ± 0.03** 0.23 ± 0.06 4 3
150 0.14 ± 0.04*** 0.24 ± 0.09 4 3
5 5 0.23 ± 0.06 0.27 ± 0.15 4 3
10 0.23 ± 0.04 1.19 ± 0.39*** 8 3
50 0.25 ± 0.06 0.50 ± 0.10** 4 3
100 0.26 ± 0.01 0.28 ± 0.06 4 3
150 0.22 ± 0.11 0.28 ± 0.09 4 3
aSingle-channel currents were recorded from cells expressing human
α7 wild type activated by 100 μM ACh in the absence or presence of
compounds 4a, 4b, and 5. τopen and τburst correspond to the time
constants of the slowest exponential component of the corresponding
histograms obtained from single-channel recordings. Values are mean
± SD. n = number of independent experiments, each from different
cell patches. N = number of cell transfections. Statistical significance
was determined by one way ANOVA followed by Bonferroni’s post
hoc tests for multiple comparisons. The asterisk symbol (*) indicates
statistical significance between the longest duration values (τopen or
τburst) in the presence of each compound with respect to those in the
absence of compounds (p < 0.05*, p < 0.01**, p < 0.001***). The
structures of compounds 4a, 4b, and 5 are shown in Scheme 1.
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of ∼3.7 times the value in the burst duration with respect to
that of the control condition (Table 2, Figure S1). In three out
of eight recordings, an additional third component showing an
∼2.8 increased duration with respect to that of the slowest
open component of the control condition was detected (0.76
± 0.31 ms, p < 0.001). However, increasing the concentration
of compound 5 to 50 μM decreased its potentiating effect, as
the burst duration was only ∼1.5-fold longer than that of the
control (Table 2). Therefore, compounds 4b and 5 only
exerted their maximal potentiation at one of the tested
concentrations, 50 and 10 μM respectively, thus showing a
more limited active concentration range compared to that of
compound 4a.
The three compounds exhibited a lower potentiation ability
at the highest concentrations of their active ranges (Table 2).
Although it is not possible to unequivocally determine from
our recordings the cause of this inhibitory effect, a possible
explanation is that it may be due to channel blockade. The dual
action of compounds mediating opposite effects on nAChR
function, such as agonism or potentiation at low concen-
trations and open-channel blockade at higher concentrations,
has been described for other ligands and arises from binding to
different sites.25,30−32 Alternatively, the compounds may have a
dual negative allosteric modulator (NAM)−PAM activity. This
possibility appears to be less probable, because such a behavior
has not been reported before for other α7 PAMs; in addition, it
has been suggested that NAMs compete for the same allosteric
sites of PAMs.12,33 Also, we cannot discard, from these
experiments, that the inhibitory activity of the compound takes
place at the same concentration range as that of its potentiating
activity. This may result in competition between potentiation
and inhibition activities and may lead to the underestimation
of its efficacy as a PAM.
By comparing the maximal potentiation evoked by
compounds 4a, 4b, and 5 using one way ANOVA followed
by Bonferroni’s post hoc tests, statistically significant differ-
ences were detected in the mean durations of the slowest open
component (p < 0.001) and bursts (p < 0.01). The maximal
enhancement of the channel open duration by compound 4b
in all the recordings was lower than that exerted by compound
4a (p < 0.001). Conversely, compound 5 prolonged openings
in only a few recordings, to a lesser extent than that of
compound 4a (p < 0.05) and without significant differences
with respect to compound 4b (p > 0.05). Also, compound 5
increased the mean burst duration in a similar manner to that
of compound 4b (p > 0.05). For both compounds, the increase
in burst duration was lower than that induced by compound 4a
(p < 0.05). Thus, considering the mean burst and open
durations as a measurement of the efficacy, the order for the
maximal PAM activity was 4a > 4b > 5.
In our experimental conditions, the main chemical species of
the phosphonic acid group in compound 5 exhibits only one
negative net charge, due to a single hydroxyl group ionized at
physiological pH 7.4. There are no charged molecules
previously reported as PAMs, so it is possible that the
presence of ionized groups gives origin to electrostatic forces
which impede or hinder hydrophobic interactions in the
allosteric site, leading to the poor effect of compound 5. On
the other hand, given that the phosphonates are not charged,
they may be capable of establishing hydrophobic interactions
in the allosteric site and inducing more significant potentiation.
A decrease in potentiation of 4b with the increase in the
aliphatic chain length of the group esterifying the phosphonic
acid was also noticeable. This effect may be due to a higher
steric hindrance, because the ability to form hydrophobic
interactions does not change substantially.
As the ability to penetrate the blood−brain barrier (BBB) is
a requirement for neurotherapeutic drugs,34,35 we also
estimated this ability for the active compounds 4a, 4b, and 5
using two different computational methods. Results from the
BOILED-egg method36 (SwissADME platform: http://www.
swissadme.ch/) predicted that 4a and 4b but not phosphonic
acid 5 can cross the BBB. Application of the online BBB
prediction server (http://www.cbligand.org/BBB/) yielded
scores of 0.110, 0.092, and 0.075 for 4a, 4b, and 5, respectively,
which are significantly higher than the minimum required for
BBB permeation (0.02).34 Thus, predictive models indicated
that our most active compound, 4a, and 4b meet the
requirements to cross the BBB.
To our knowledge, this is the first work exploring
phosphonate groups as nAChR modulators. Some background
reports sustained our selection of phosphonate groups as
substituents for the triazole heterocycle, because they are
present in some AChE inhibitors, which in turn, are potential
candidates to act directly on nAChRs as allosteric agents. Some
of these compounds potentiate nAChR function at low
concentrations but exert a negative effect due to the open-
channel blockade at higher concentrations,31,32 in agreement
with our observations for some of the 1,2,3-triazole derivatives.
As compound 4a was the synthetic phosphonate-function-
alized 1,2,3-triazole showing the most potent and efficacious
PAM activity, we explored its effects at the macroscopic level
and in further detail at the microscopic level, and we also used
it to perform SAR studies.
Detailed Characterization of Compound 4a as a Positive
Allosteric Modulator for α7. In order to determine whether
compound 4a behaves as a type I or a type II PAM on α7
receptors, we evaluated, by whole-cell recordings, its effects on
macroscopic currents, which result from the activation of all
receptors in a cell.
ACh elicited rapid macroscopic currents from cells
expressing human α7, which reached the peak in about 5−
10 ms and decayed in the continuous presence of the agonist
due to desensitization (Figure 3A). The current decays were
fitted by two exponential components with time constants of
∼30−50 (τfast) and ∼500−1200 (τslow) ms under the present
experimental conditions. The desensitization rate of α7
receptors cannot be accurately determined from the decay
rate of macroscopic currents, because as it is extremely fast, its
measurement is limited by the speed of the perfusion system.
Nevertheless, a decrease of the desensitization rate, as that
exerted by type II PAMs, is translated into a decrease of the
decay rate, which can be quantified by the increase of the decay
time constants.3,25
We recorded macroscopic currents evoked by ACh in the
absence and presence of compound 4a (50 μM) in the same
cell and averaged from different cells the relative changes for
peak current and net charge, and the absolute values for the
decay time constants. Compound 4a significantly enhanced the
peak current 1.51 ± 0.26 times (p < 0.001, n = 7, N = 3, Figure
3A). The decay in the presence of the compound was also
fitted by two components, τfast = 29 ± 6 ms and τslow = 901 ±
649 ms, which did not markedly change with respect to the
components of the control current (τfast = 37 ± 7 ms and τslow
= 1294 ± 1034 ms). The fast component showed a very slight
increase compared to that of the control (p = 0.03), but the net
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charge remained without changes (1.02 ± 0.22, p > 0.05), with
a net charge/peak ratio of 0.68 ± 0.15. Typically, type I PAMs
show net charge/peak ratios of about one, whereas type II
PAMs show higher values; this is because they also decrease
the current decay rate, which leads to a large increase of the net
charge. Therefore, compound 4a recapitulates the macroscopic
potentiation pattern of type I PAMs.
Figure 3B,C illustrates and summarizes the actions of
compound 4a at the microscopic level. As mentioned above,
potentiation started to be evident at 5 μM and maintained its
maximal level in the 10−50 μM concentration range (Figure
3B,C). At 100 μM, the potentiating effect was reduced but still
detectable, whereas at 150 μM, there was no potentiation;
instead, a slight reduction in the open duration was observed.
For α7 activated by ACh, a wide range of channel
amplitudes are detected, because the brief open-channel
lifetime does not allow full amplitude resolution.27,28 Hence,
to explore if compound 4a alters channel amplitude, we
constructed amplitude histograms only for events longer than
0.3 ms, which are fully resolved in our system. The maximal
single-channel amplitude did not exhibit significant differences
in the presence (9.76 ± 0.37 pA) or absence of compound 4a
(9.99 ± 0.41 pA, p > 0.05, n = 4, N = 4, Figure 3B), as
described for other α7 PAMs.25,28,29
Overall, compound 4a increased the macroscopic peak
current elicited by ACh without significantly decreasing the
desensitization rate, which is the hallmark of a type I PAM
behavior. It did not affect the single-channel conductance but
prolonged the duration of openings (∼4 times) and induced
frequent activation in sustained episodes or bursts (∼7-fold
longer duration). These properties allowed us to classify
compound 4a as the first synthetic phosphonate-functionalized
1,2,3-triazole with type I α7-PAM activity.
Structural Determinants of Compound 4a Potentiation.
The locations of α7-PAM binding sites have not been
determined unequivocally, because crystal structures of α7
either alone or in complex with modulators have not been
reported yet. However, the use of chimeric and/or mutant
receptors has provided an approximation of PAM binding sites
and has allowed the discovery of amino acids whose presence
is essential for modulation, either at the binding site or in the
transduction pathway. In order to provide further information
about the α7-PAM activity of compound 4a, we explored its
activity in the chimeric receptor α7-5HT3A (Figure 4A) and in
the quintuple mutant α7 TSLMF receptor (Figure 4B), which
constitute valuable approaches to identify structural determi-
nants of potentiation.
The chimeric α7-5HT3A receptor carries human α7
sequence in the extracellular domain, up to the beginning of
the first transmembrane domain, and it carries mouse 5-HT3A
sequence thereafter. It has been used as a model of the
extracellular domain of α7 as well as a way to define domains
involved in drug action5,37 (Figure 4A). The chimeric receptor
activated by 500 μM ACh exhibited a slow open component of
5.39 ± 0.18 ms (area 0.20 ± 0.10) and a mean burst duration
of 13.33 ± 3.16 ms (n = 5, N = 4). In the presence of 50 μM
compound 4a, there were no statistically significant differences
in the area and the duration of the longest openings (5.01 ±
0.56 ms, area 0.16 ± 0.09) and in the mean duration of bursts
elicited by ACh (10.89 ± 3.06 ms, n = 4, N = 3, p > 0.05 in
each case, determined by the two-tailed Student’s t-test). The
open time and burst duration histograms were fitted by three
Figure 3. Positive allosteric modulation of compound 4a on α7
receptors. (A) Representative whole-cell α7 currents evoked by ACh
(black traces) and ACh coapplied with 50 μM compound 4a (gray
traces). The horizontal bars over the currents indicate the application
of agonist alone (black) or together with the compound (gray).
Holding potential: 50 mV. (B) Typical traces of α7 single-channel
currents in the presence of 100 μM ACh with and without 5−150 μM
compound 4a. Membrane potential: −70 mV. Filter: 9 kHz. (C)
Mean open (τopen, black) and burst (τburst, gray) durations in the
presence of different concentrations of compound 4a. The data
correspond to the duration of the slowest component of each
corresponding histogram. Data are plotted as mean ± SD. The
number of independent experiments (n) and the number of cell
transfections (N) for each condition are shown in Table 2. Statistical
significance was determined by one way ANOVA followed by
Bonferroni’s post hoc tests for multiple comparisons. The asterisk
symbol (*) indicates statistical significance between the longest
duration values (τopen or τburst) in the presence of each compound
with respect to those in the absence of compounds (p < 0.05*, p <
0.01**, p < 0.001***). The structures of compounds 4a, 4b, and 5
are shown in Scheme 1.
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exponential components in the absence and presence of
compound 4a (Figure 4C).
Recordings of α7-5HT3A were carried out with low-calcium
solutions to avoid channel block. This could interfere with
potentiation, because Ca2+ has been shown to act as a PAM of
α7 and also to enhance potentiation by some modulators.38,39
However, some degree of potentiation could have still been
observed in our recording conditions, because though at a
lower concentration, Ca2+ was still present in the solution (0.2
mM); it could also have still been observed because a
prototype type I PAM, 5-HI, has been shown to potentiate the
same chimeric receptor under low calcium concentra-
tion.27,29,40 Thus, despite the fact that other type I PAMs
can positively modulate the chimera,29,40 compound 4a was
incapable of potentiating it, suggesting a role of the ECD−
TMD interface or the TMD of α7 for potentiation.
The quintuple mutant α7 TSLMF receptor contains
mutations in five residues of TMD in α7 that inhibit
potentiation by type II PAMs, which led us to propose the
region or cavity lined by these residues as a PAM binding
site41,42 (Figure 4B). However, the mutations differentially
affect potentiation by type I PAMs. Whereas some type I
PAMs, such as NS-1738 and flavonoids, lose their ability to
potentiate the quintuple mutant receptor,25,43 others, such as
5-HI, keep such an ability.29 The open and burst duration
histograms of α7 TSLMF activated by 100 μM ACh were fitted
by three exponential components, which showed no differ-
ences in the absence and presence of compound 4a (Figure
4C). In the absence of 4a, the mean duration of the slowest
open component was 1.17 ± 0.32 ms (area 0.18 ± 0.10) and
the mean burst duration was 2.03 ± 0.77 ms (n = 5, N = 4). In
the presence of 50 μM compound 4a, there were no significant
differences in the open duration and area (1.04 ± 0.20 ms, area
0.17 ± 0.07) or in the burst duration (1.76 ± 0.05 ms, n = 4, N
= 3, p > 0.05 in each case determined by the two-tailed
Student’s t-test). In summary, the five transmembrane residues
or at least some of them are essential for potentiation by
compound 4a, either by conforming the binding site or by
being involved in the transduction pathway.
Type II PAMs, and some type I PAMs, such as NS-1738,
LY-2087101, ivermectin, and flavonoids, share some of the
transmembrane structural determinants.25,29,41,43,44 It has been
proposed that PAMs may use overlapping sites at the
transmembrane cavity with type I PAMs binding in an upper
position related to type II PAMs.13,43,44 For some PAMs,
including type I PAMs such as ivermectin,44 an important
delay in the potentiation has been detected from macroscopic
currents, whereas for compound 4a (Figure 3A) as well as for
other type I PAMs, such as NS-1738 and flavonoids,25,29 no
significant delays have been observed. It is therefore possible
that the time required for exerting potentiation by different
PAMs may be determined by their locations and dispositions
at the overlapping transmembrane binding sites, the pathway
used to reach their transmembrane sites, and their interaction
Figure 4. Structural determinants of potentiation of compound 4a. (A) View of a chimeric α7-5HT3A subunit.
5 (B) View of a quintuple mutant α7
TSLMF subunit, showing the three helices of the TMD (M1, M2, and M3), carrying the five mutations that make α7 insensitive to the prototype
type II PAM PNU-12059642 (S223T and A226S in M1, M254L in M2, and I281 M and V288F in M3). (C, left side) Typical traces from single-
channel recordings of α7-5HT3A activated by 500 μM ACh alone or combined with 50 μM compound 4a (top) and of α7 TSLMF activated by
100 μM ACh alone or combined with 50 μM compound 4a (bottom). Channel openings are shown as upward deflections. (C, right side)
Representative open and burst duration histograms for each condition. Membrane potential: −70 mV. Filter: 9 kHz.
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with the lipid membrane, all governed by their chemical
properties.
We showed that compound 4a shares transmembrane
structural determinants of potentiation with other chemically
nonrelated PAMs. This finding suggests a promising α7
selectivity of compound 4a, because the transmembrane
residues are not well-conserved among Cys-loop receptors;
most α7 PAMs requiring these residues for their action do not
potentiate or even inhibit other receptors of the family,
including 5-HT3A and other nAChR subtypes.
10,25,45,46
Nevertheless, future studies are needed to experimentally
Scheme 2. Synthesis of 1,4-Disubstituted 1,2,3-Triazole Series IIa
a(A) Synthesis of homologues of phosphonate 4a. Reagents and conditions: (Ai) (a) HCl/H2O, (b) NaNO2(aq), (c) NaN3, rt (90%); (Aii)
CuNPs/C (5 mol %), H2O, NaN3, 70 °C; and (Aiii) CBr4, PPh3, DCM, from 0 °C to rt (Civ) P(OMe)3, 110 °C. (B) Synthesis of a 4a analogue
with inversion of substituents on the triazole ring. Reagents and conditions: (Bi) (H2CO)n, K2CO3, MeOH, 65 °C (quantitatively (quant)); (Bii)
(a) Tf2O, 2,6-Lut, DCM, from −78 °C to 0 °C (83%) and (b) NaN3, DMF, 0 °C (83%); (Biii) (a) CuI, K2CO3, TBAI, MeCN, 80 °C (93%) and
(b) K2CO3, MeOH, 0 °C (quant); and (Biv) CuNPs/C (10 mol %), triethylamine (TEA), THF, 65 °C (54%). (C) Synthesis of benzyl derivative
of 4a. Reagents and conditions: (Ci) CuNPs/C (5 mol %), H2O, NaN3, 70 °C (84%); (Cii) CBr4, PPh3, DCM, from 0 °C to rt (85%); and (Ciii)
P(OMe)3, 110 °C (67%).
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Table 3. Single-Channel Parameters of α7 Receptors in the Presence of Compound Series IIa
compound τopen (ms) τburst (ms) n N
0.27 ± 0.03 0.32 ± 0.06 7 6
4a 50 μM 1.06 ± 0.04*** 2.26 ± 0.34*** 4 3
10a 50 μM 0.31 ± 0.16### 0.30 ± 0.11### 10 5
10b 50 μM 0.23 ± 0.08### 0.28 ± 0.11### 7 4
15 50 μM 0.45 ± 0.13** ### 1.27 ± 0.24*** ### 4 3
19 50 μM 0.29 ± 0.02### 0.37 ± 0.07### 5 3
aSingle-channel currents were recorded from cells expressing human α7 wild type activated by 100 μM ACh in the absence or presence of synthetic
compounds. τopen and τburst correspond to the slowest component of the corresponding histograms. Values are mean ± SD. n = number of
independent experiments, each from different cell patches. N = number of cell transfections. Statistical significance was determined by one way
ANOVA followed by Bonferroni’s post hoc tests for multiple comparisons. The different symbols indicate statistically significant differences
compared to the control in the absence of compounds (*) and compared to the condition in the presence of compound 4a (#). The number of
symbols (one, two, or three) indicates different significant p-values independently of the type of symbol (for instance, p < 0.05*, p < 0.01**, p <
0.001***). The structures of compounds are shown in Scheme 2.
Figure 5. Effects of the 1,4-disubstituted 1,2,3-triazole series II on α7 receptors at the single-channel level. (A, left) Typical traces of α7 single-
channel currents in the presence of 100 μM ACh alone or combined with 50 μM of each series II compound. Channel openings are shown as
upward deflections. (A, right) Representative open and burst duration histograms for each condition. Membrane potential: −70 mV. Filter: 9 kHz.
(B) Bar chart showing the mean open (τopen) and burst (τburst) durations in the presence of the different compounds. τopen corresponds to the
longest duration component of the corresponding open time histogram. Data are plotted as mean ± SD. The number of independent experiments
(n) and the number of cell transfections (N) for each condition are shown in Table 3. Statistical significance was determined by one way ANOVA
followed by Bonferroni’s post hoc tests for multiple comparisons. The asterisk symbol (*) and the pound symbol (#) indicate comparison with
control without compounds and with the compound 4a condition, respectively. The number of symbols (one, two, or three) indicates different
significant p-values independently of the type of symbol (for instance, p < 0.05*, p < 0.01**, p < 0.001***).
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determine the selectivity of this novel series of compounds
among different neurotransmitter receptors.
Synthesis of 1,4-Disubsituted 1,2,3-Triazoles Series II: SAR
Studies. On the basis of the biological results obtained for the
1,2,3-triazole series I, we selected dimethyl phosphonate 4a as
lead compound and performed SAR studies in order to find
derivatives with enhanced activity. The strategies employed,
shown in Scheme 2, can be classified into three categories: (i)
modification of chain length between the triazole-aryl group
and triazole-phosphonate group, i.e., the generation of a
homologous series, (ii) inversion of substituent positions in the
triazole ring, and (iii) variation of the aryl group attached to
the triazole ring.
None of these strategies involves the modification of the
phosphonate group, which seemed to be essential for the α7-
PAM activity exerted by compound 4a. Synthetic routes for
obtaining these derivatives are shown in Scheme 2, and
experimental details for the synthesis of precursors are
described in the Supporting Information.
Generation of a Homologous Series. To study the effect of
the chain length on α7-PAM activity, we proposed the
synthesis of two derivatives: phosphonates 10a and 10b from
alcohols 8a and 8b, respectively (Scheme 2A). As previously
reported, 8a-b can be obtained through the CuAAC
reaction.47,48 Compound 10a presents the naphthyl group
directly attached to the triazole ring, modifying both the
geometry and electronic distributions of the aromatic ring. On
the other hand, compound 10b presents an elongation of the
alkyl chain between the triazole moiety and phosphonate
group.
1-Azidonaphthalene (7) was obtained in excellent yield from
1-aminonaphthalene (6) via diazonium salt (Supporting
Information). It was subsequently submitted to the click
reaction with propargyl alcohol (2), in the presence of CuNPs/
C (5 mol %), to give triazole 8a, whereas compound 1 was
reacted with 3-butyn-1-ol, in the presence of sodium azide and
the same catalyst, to give compound 8b. Both alcohols were
transformed in their corresponding bromides via the Appel
reaction and then subjected to the Arbuzov reaction with
trimethyl phosphite, affording the desired products 10a and
10b, with higher yields when compared to those of the
Michaelis−Becker reaction.
Inversion of Substituent Positions in Triazole Ring.
Dimethyl phosphite was added to paraformaldehyde (PFA)
in methanol (MeOH) to afford, quantitatively, hydroxyme-
thylphosphonate 11 (Scheme 2B), which was converted in
triflate 12 by treatment with Tf2O in the presence of 2,6-
lutidine in DCM. Reaction of the triflate derivative with
sodium azide gives the desired dimethyl (azidomethyl)-
phosphonate 13 (quant). On the other hand, alkyne 14 was
obtained through copper-promoted coupling of chloride 1 and
trimethylsilylacetylene and, subsequently, cleavage of the silyl
group, in the presence of K2CO3 (for experimental details see
the Supporting Information). Finally, the CuAAC reaction
between 13 and 14 was carried out in tetrahydrofuran/
triethylamine (THF/TEA), with CuNPs/C as the catalyst,
affording the desired phosphonate 15 (54%).
Variation of Aryl Group Attached to the Triazole Ring. In
order to evaluate the importance of the naphthyl group in α7-
PAM activity exerted by 4a, an analogue bearing a benzyl
group was synthesized (Scheme 2C). The synthetic approach
employed was similar to the one used for obtaining
phosphonate 4a. The main difference was that for obtaining
compound 19, where the Arbuzov reaction was used instead of
the Michaelis−Becker reaction. Synthesis of this derivative
started with the multicomponent click reaction of benzyl
bromide 16 with propargylic alcohol, which afforded triazole
17,49,50 followed by the Appel reaction, yielding bromide 1851
and then reacted with P(OMe)3 to give the desired
phosphonate 19.
Functional Characterization of Series II Compounds on
α7 Receptors: SAR Studies. To evaluate the α7-PAM activity
of the synthesized compound series II, we performed single-
channel recordings in the cell-attached configuration in
BOSC23 cells expressing the human α7 receptor. The
compounds were added to the pipet solution at a
concentration of 50 μM together with 100 μM ACh to
compare their effects with those of the original compound 4a
at the same concentrations.
In the majority of the recordings, no potentiation of α7 by
compound 10a was detected (Table 3, Figure 5). The open
time and burst duration histograms were fitted by two
exponential components and were similar to those of the
control condition (Figure 5A). From a total of ten recordings
in the presence of compound 10a, only one showed a slight
increase in the duration of the slowest open component (∼1
ms), and three recordings showed a slight increase of the mean
burst duration (1.28 ± 0.27 ms). The increase of the mean
burst duration was statistically significant with respect to the
control condition in the absence of modulators (p < 0.05);
however, it was detected in less than 30% of the recordings and
was lower compared to that exerted by compound 4a (p <
0.05). Overall, the shortening of the triazole-aryl group length
in compound 10a diminished the α7-PAM activity with respect
to the lead compound.
Compound 10b did not potentiate α7, because there were
no significant differences in the mean open and burst durations
with respect to the control condition (Table 3, Figure 5). Both
histograms were fitted by two exponential components, similar
to histograms of control recordings (Figure 5A). Therefore,
the elongation of the triazole-phosphonate chain revoked the
α7-PAM activity of compound 4a.
Compound 15 carrying the inverted triazole exhibited α7-
PAM activity, which was evidenced by the increased open-
channel lifetime and prolonged bursts (Table 3, Figure 5). The
open time and burst duration histograms were described by
three exponential components (Figure 5A). The first two open
components were similar to those of the control condition, and
the main difference was given by the appearance of a third long
duration component with low relative area. The duration of
this component was statistically significantly longer than that of
the slowest open component of the control condition (Figure
5B). Also, the mean burst duration was prolonged in the
presence of compound 15 (Figure 5B). Although potentiation
was significant, the degree of potentiation of compound 15 was
slightly lower than that exerted by compound 4a (Table 3,
Figure 5).
The analysis of compound 19 revealed that the variation of
the aryl group annulled the α7-PAM activity of the original
triazole derivative. The mean open and burst durations did not
show significant differences with the control condition and
were shorter than those in the presence of compound 4a
(Table 3, Figure 5). Both histograms were fitted by two
exponential components, such as those described for α7 in the
presence of ACh alone (Figure 5A).
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Therefore, the inversion of substituent positions in the
triazole ring was the only SAR strategy that preserved α7-PAM
activity of the triazole derivatives, although this activity was
slightly lower than that exerted by the original structure. The
retention of PAM activity may be due to the fact that the steric
disposition of the substituents on the triazole ring of
compound 15 is still similar to that of compound 4a.
The SAR modifications in this work led to compounds
lacking positive modulatory activity or with the same effect as
that of the original structure. These results are in agreement
with previous reports demonstrating that minimal changes in
the chemical structure of a modulator can lead to dramatic
differences in the pharmacological profile of the compound,
involving the interconversion to allosteric agonists, silent
allosteric modulators (SAMs), and NAMs.8,33 In this case,
from compound 4a we obtained compound 15, which retained
α7-PAM activity, and compounds 10a, 10b, and 19, which lost
this activity. This lack of PAM activity may result from either
the conversion to SAM activity or the loss of the binding
capacity of the compound to the allosteric site.
Our study opens doors for future modifications through
SAR studies, which are almost unlimited and offer the
possibility to generate a broad range of structures for the
search of promising therapeutic compounds.
■ CONCLUSIONS
Positive allosteric modulation of α7 nAChRs has emerged as a
promising therapeutic strategy for neurological, inflammatory,
and neurodegenerative disorders with a dysfunction in
cholinergic signaling.3,7,9 The development of new synthetic
PAMs offers not only the possibility of providing prototype
compounds but also the chance of improving pharmacological
properties, such as efficacy, potency, selectivity, and reduced
side effects. Here, we synthesized a novel series of 1,4-
disubstituted 1,2,3-triazoles with aryl and phosphonate groups,
whose biological activities on α7 receptors were evaluated for
the first time by electrophysiological techniques.
In the context of nAChR ligands, there is only one series of
PAMs with triazoles in their structure, in particular the isomer
1,2,4-triazole.12,13 In contrast, the isomer 1,2,3-triazole was
explored for the first time in the present work. Triazole features
that make them optimal in medicinal chemistry include the
formation of hydrogen bonds and dipole−dipole and π−π
interactions; the stability of hydrolysis, metabolic degradation,
and redox conditions; and the water solubility.14 Several
triazoles have been reported with a wide range of biological
activities.14,15 Another singularity is that substitutions in
positions 1 and 4 of the triazole ring give a place, in terms
of distance and planarity, to nonclassical bioisosteres of the
amide group, one of the most frequent in bioactive drugs.14,16
Also, phosphonates have been unexplored among the nAChR
ligands but are present in several AChE inhibitors.20 The
unique biological properties of phosphonates lie in their highly
stable C−P bond, which makes them hydrolysis resistant and
capable of mimicking phosphorus−oxygen and carbon−oxygen
bonds of endogenous molecules.19,20
In conclusion, we here designed and synthesized a novel
series of 1,4-disubstituted 1,2,3-triazole derivatives with aryl
and phosphonate groups that exhibited α7-PAM activity, the
compound functionalized with the methyl phosphonate group
being the most efficacious one. We deciphered the molecular
mechanism of action, classified the most active compound as a
type I PAM, identified transmembrane amino acids required
for potentiation, and applied several SAR strategies from its
structure. We propose phosphonate-functionalized 1,2,3-
triazoles not only as a novel pharmacophore with intrinsic
α7-PAM activity but also as a scaffold for developing new
potential therapeutic agents for neurological diseases.
■ MATERIALS AND METHODS
Synthetic Procedures. General. All moisture sensitive reactions
were carried out under a nitrogen atmosphere. Anhydrous
tetrahydrofuran was freshly distilled from sodium/benzophenone
ketyl, and DCM was distilled from CaH2. All starting materials were
of the best available grade (Aldrich, Merck) and were used without
further purification. Commercially available copper(II) chloride
dihydrate was dehydrated upon it being heated in an oven (150 °C,
60 min) prior to use for the preparation of CuNPs. Column
chromatography was performed with Merck silica gel 60 (0.040−
0.063 μm, 240−400 mesh) and hexane/ethyl acetate (EtOAc),
MeOH/DCM, or MeOH/EtOAc as the eluent. Reactions were
monitored by thin-layer chromatography (TLC) on silica gel plates
(60F-254) visualized under UV light and/or using 5% phosphomo-
lybdic acid in ethanol. Nuclear magnetic resonance (NMR) spectra
were recorded on a Bruker ARX-300 spectrometer (300 MHz 1H, 75
MHz 13C, 121 MHz 31P). Chemical shifts (δ) were reported in parts
per million (ppm) from tetramethylsilane (TMS) using the residual
solvent resonance (CDCl3: 7.26 ppm for
1H NMR, 77.16 ppm for 13C
NMR). Multiplicities were abbreviated as follows: s = singlet, d =
doublet, t = triplet, q = quartet, m = multiplet, and brs = broad
signal). Coupling constants (J) were reported in Hz. Melting points
(mps) were uncorrected.
Preparation of the CuNPs/C. Anhydrous copper(II) chloride (135
mg, 1 mmol) was added to a suspension of lithium (14 mg, 2 mmol)
and 4,4′-di-tert-butylbiphenyl (DTBB, 27 mg, 0.1 mmol) in dry THF
(2 mL) at room temperature under a nitrogen atmosphere. The
reaction mixture, which was initially dark brown, rapidly changed to
black, indicating that the suspension of copper nanoparticles was
formed. This suspension was diluted with THF (10 mL), followed by
the addition of activated carbon (0.8 g). The resulting mixture was
stirred for 1 h at room temperature, filtered, and the solid successively
washed with THF (5 mL) and ethanol (10 mL), and then, it was
dried under vacuum. The catalyst prepared in this way did not require
dry or inert atmosphere storage and was used without any
pretreatment in all CuAAC reactions.
General Procedure for the 1,3-Dipolar Cycloaddition Catalyzed
by CuNPs/C in Water. Sodium azide (72 mg, 1.1 mmol), the organic
halide (1 mmol), and the alkyne (1 mmol) were added to a
suspension of CuNPs/C (40 mg, 5 mol % Cu) in H2O (2 mL). The
reaction mixture was warmed to 70 °C and monitored by TLC until
there was total conversion of the starting materials. Water (10 mL)
was added to the resulting mixture followed by extraction with EtOAc
(3 × 10 mL). The collected organic phases were dried with Na2SO4,
and solvent was removed under vacuum; the product was purified by
flash column chromatography (hexane/EtOAc) to give the corre-
sponding triazole.
{1-[(Naphthalen-1-yl)methyl]-1H-1,2,3-triazol-4-yl}methanol (2).
The compound is a white solid (196 mg, 82%). mp: 132−134 °C. Rf
= 0.29 (EtOAc). 1H NMR (CD3CN): δ 8.05−7.98 (m, 1H), 7.89−
7.81 (m, 2H), 7.51 (s, 1H), 7.50−7.44 (m, 2H), 7.44−7.38 (m, 1H),
7.37−7.32 (m, 1H), 5.91 (s, 2H), 4.45 (d, J = 5.1 Hz, 2H), 3.13 (t, J =
5.1 Hz, 1H). 13C NMR (75 MHz, CD3OD): δ 148.0, 135.4, 132.5,
131.9, 130.8, 129.9, 128.8, 128.00, 127.95, 127.3, 126.5, 124.0, 56.4,
52.9.
{[1-(Naphthalen-1-yl)-1H-1,2,3-triazol-4-yl]methanol (8a). This
compound was directly synthesized from 1-azidonaphthalene. It is a
pale yellow solid (180 mg, 80%). mp: 109−110 °C. Rf = 0.47
(EtOAc).1H NMR (CDCl3): δ 8.04−7.97 (m, 1H), 7.96−7.91 (m,
2H), 7.63−7.46 (m, 5H), 4.98 (s, 2H), 3.41 (s, 1H). 13C NMR
(CDCl3): δ 147.7, 134.1, 133.6, 130.4, 128.5, 128.3, 127.9, 127.1,
125.0, 124.5, 123.6, 122.3, 56.5. Spectroscopic data are in agreement
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with previously reported 1H and 13C NMR characterization data for
the title compound.47
2-{1-[(Naphthalen-1-yl)methyl]-1H-1,2,3-triazol-4-yl}ethan-1-ol
(8b). The compound is a white solid (164 mg, 65%). mp: 145−146.5
°C. Rf = 0.26 (EtOAc).
1H NMR (CDCl3): δ 8.01−7.93 (m, 1H),
7.93−7.86 (m, 2H), 7.57−7.49 (m, 2H), 7.49−7.40 (m, 2H), 7.17 (s,
1H), 3.87 (c, J = 5.9 Hz, 2H), 2.84 (t, J = 5.9 Hz, 2H), 2.65 (s, 1H).
13C NMR (CDCl3): δ 145.8, 133.9, 131.2, 130.0, 129.9, 128.9, 127.9,
127.3, 126.4, 125.4, 122.9, 121.4, 61.6, 52.3, 28.7. Spectroscopic data
are in agreement with previously reported 1H and 13C NMR
characterization data for the title compound.48
(1-Benzyl-1H-1,2,3-triazol-4-yl)methanol (17). The compound is
a white solid (159 mg, 84%). mp: 74−75 °C. Rf = 0.12 (50% EtOAc/
hexane). 1H NMR (CDCl3): δ 7.45 (s, 1H), 7.36−7.29 (m, 3H),
7.26−7.21 (m, 2H), 5.45 (s, 2H), 4.70 (s, 2H), 4.17−3.69 (s, 1H).
13C NMR (CDCl3): δ 148.3, 134.6, 129.2, 128.8, 128.2, 121.9, 56.2,
54.2. Spectroscopic data are in agreement with previously reported 1H
and 13C NMR characterization data for the title compound.49,50
Dimethyl ({4-[(Naphthalen-1-yl)methyl]-1H-1,2,3-triazol-1-yl}-
methyl)phosphonate (15). In this case, CuAAC was carried out in
THF/TEA instead of water. Alkyne 14 (0.05 g, 0.3 mmol) and the
organic azide 13 (0.049 g, 0.3 mmol) were added to a suspension of
CuNPs/C (24 mg, 10 mol % Cu) in THF (2 mL) and TEA (42 μL,
0.3 mmol). The reaction mixture was warmed to 65 °C and
monitored by TLC until there was total conversion of the starting
materials. Water (10 mL) was added to the resulting mixture followed
by extraction with EtOAc (3 × 10 mL). The collected organic phases
were dried with Na2SO4, and solvent was removed under vacuum; the
product was purified by flash column chromatography (DCM/
MeOH) to give phosphonate 15 as a colorless oil, (54 mg, 54%). Rf =
0.65 (10% MeOH/DCM). 1H NMR (CDCl3): δ 8.03−7.94 (m, 1H),
7.88−7.79 (m, 1H), 7.79−7.71 (m, 1H), 7.48−7.42 (m, 2H), 7.42−
7.37 (m, 2H), 7.21−7.17 (m, 1H), 4.63 (d, J = 13.0 Hz, 2H), 4.52 (s,
2H), 3.65 (d, J = 10.9 Hz, 6H). 13C NMR (CDCl3): δ 148.2, 134.8,
134.0, 131.7, 128.8, 127.7, 127.0, 126.2, 125.8, 125.7, 124.1, 123.0,
53.65 (d, J = 6.6 Hz), 45.09 (d, J = 156.0 Hz), 30.1. 31P NMR
(CDCl3): δ 18.4.
General Procedure for Bromination of Alcohols (Appel
Reaction). To a cooled solution (0 °C) of the alcohol (0.5 mmol)
and CBr4 (0.6 mmol) in dry DCM (10 mL), PPh3 (0.8 mmol) was
slowly added. Then, the reaction mixture was stirred at room
temperature until there was total conversion of the starting materials
(1 h, monitored by TLC). The solvent was removed under vacuum,
and the residue was purified by flash column chromatography
(hexane/EtOAc) to give the corresponding bromide.
4-(Bromomethyl)-1-[(naphthalen-1-yl)methyl]-1H-1,2,3-triazole
(3). The compound is a pale yellow solid (120 mg, 80%). mp: 108−
109 °C. Rf = 0.35 (50% EtOAc/hexane).
1H NMR (CDCl3): δ 7.98−
7.86 (m, 3H), 7.56−7.50 (m, 2H), 7.50−7.46 (m, 1H), 7.46−7.42
(m, 1H), 7.34 (s, 1H), 5.96 (s, 2H), 4.47 (s, 2H). 13C NMR
(CDCl3): δ 144.9, 134.1, 131.3, 130.3, 129.6, 129.1, 128.2, 127.5,
126.6, 125.5, 122.9, 122.8, 52.6, 21.7.
4-(Bromomethyl)-1-(naphthalen-1-yl)-1H-1,2,3-triazole (9a).
The compound is an orange oil (118 mg, 82%). Rf = 0.71 (50%
EtOAc/hexane). 1H NMR (CDCl3): δ 8.02 (m, 1H), 8.00−7.93 (m,
2H), 7.66−7.50 (m, 5H), 4.73 (s, 2H). 13C NMR (CDCl3): δ 144.8,
134.3, 133.5, 130.8, 128.41, 128.35, 128.2, 127.3, 125.6, 125.1, 123.7,
122.3, 77.6, 77.2, 76.7, 21.6.
4-(2-Bromoethyl)-1-[(naphthalen-1-yl)methyl]-1H-1,2,3-triazole
(9b). The compound is a pale yellow solid (115 mg, 73%). mp: 159−
161 °C. Rf = 0.61 (50% EtOAc/hexane).
1H NMR (CDCl3): δ 7.99−
7.89 (m, 1H), 7.89−7.80 (m, 2H), 7.52−7.40 (m, 3H), 7.39−7.32
(m, 1H), 7.22 (s, 1H), 5.90 (s, 2H), 3.54 (t, J = 7.0 Hz, 2H), 3.14 (t, J
= 7.0 Hz, 2H). 13C NMR (CDCl3): δ 145.0, 133.8, 131.0, 129.93,
129.87, 128.9, 127.6, 127.2, 126.3, 125.3, 122.8, 52.1, 31.4, 29.4.
1-Benzyl-4-(bromomethyl)-1H-1,2,3-triazole (18). The compound
is a pale yellow solid (107 mg, 85%). mp: 135−136 °C. Rf = 0.60
(50% EtOAc/hexane). 1H NMR (CDCl3): δ 7.49 (s, 1H), 7.40−7.35
(m, 3H), 7.31−7.25 (m, 2H), 5.51 (s, 2H), 4.54 (s, 2H). 13C NMR
(CDCl3): δ 145.1, 134.4, 129.3, 129.0, 128.3, 122.8, 54.4, 21.7.
Spectroscopic data are in agreement with previously reported 1H and
13C NMR characterization data for the title compound.51
General Procedure for the Synthesis of Phosphonates via
Michaelis-Becker Reaction. To a stirred suspension of NaH (2
mmol) in dry dimethylformamide (DMF, 3 mL), H-phosphonate (2
mmol) was slowly added. After 30 min, a solution of the brominated
compound (0.5 mmol) in DMF (2 mL) was added, and the mixture
was stirred overnight at room temperature. The reaction was
quenched with H2O and extracted with EtOAc (3 × 10 mL). The
organic layers were washed with brine, dried over Na2SO4, filtered,
and evaporated. The residue was purified by flash column
chromatography (MeOH/DCM or MeOH/EtOAc) to afford the
corresponding phosphonates.
Dimethyl ({1-[(Naphthalen-1-yl)methyl]-1H-1,2,3-triazol-4-yl}-
methyl)phosphonate (4a). The compound is a colorless oil (126
mg, 76%). Rf = 0.50 (10% MeOH/DCM).
1H NMR (CDCl3): δ
8.16−8.07 (m, 1H), 8.00−7.90 (m, 2H), 7.64 (d, J = 2.4 Hz, 1H),
7.61−7.52 (m, 2H), 7.52−7.47 (m, 1H), 7.47−7.40 (m, 1H), 6.00 (s,
2H), 3.63 (d, J = 10.9 Hz, 6H), 3.30−3.19 (m, 2H). 13C NMR
(CDCl3): δ 139.36 (d, J = 7.8 Hz), 139.3, 134.8, 132.2, 131.9, 130.3,
129.8, 128.5, 127.8, 127.2, 126.5, 124.18 (d, J = 5.0 Hz), 53.39 (d, J =
6.5 Hz), 52.5, 23.35 (d, J = 141.4 Hz). 31P NMR (CDCl3): δ 27.2.
Diethyl ({1-[(Naphthalen-1-yl)methyl]-1H-1,2,3-triazol-4-yl}-
methyl)phosphonate (4b). The compound is a colorless oil (125
mg, 70%). Rf = 0.64 (10% MeOH/EtOAc).
1H NMR (CDCl3): δ
7.97−7.90 (m, 1H), 7.90−7.84 (m, 2H), 7.52−7.46 (m, 2H), 7.46−
7.40 (m, 2H), 7.37 (d, J = 2.3 Hz, 1H), 5.94 (s, 2H), 4.24−4.14 (m,
4H), 3.21 (d, J = 20.5 Hz, 2H), 1.14 (t, J = 7.1 Hz, 6H). 13C NMR
(CDCl3): δ 138.7 (d, J = 6.6 Hz), 134.0, 131.2, 130.1, 129.9, 129.0,
128.0, 127.3, 126.4, 125.4, 122.9, 122.7 (d, J = 4.1 Hz), 62.42 (d, J =
6.6 Hz), 52.6, 24.2 (d, J = 142.7 Hz), 16.3 (d, J = 6.0 Hz). 31P NMR
(CDCl3): δ 24.72.
({1-[(Naphthalen-1-yl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-
phosphonic acid (5). TMSBr (0.065 mL, 0.492 mmol) was added to
a solution of the phosphonate 4a (0.059 g, 0.164 mmol) in anhydrous
DCM (5 mL). After we stirred the solution for 5 h at room
temperature, it was concentrated under reduced pressure. Then,
MeOH (5 mL) was added, and the mixture was stirred for 30 min at
room temperature. The solvent was evaporated, and the product was
dried under vacuum to afford 6 (white solid, 43 mg, 85%). mp: 150−
152 °C. Rf = 0.10 (10% MeOH/EtOAc).
1H NMR (CD3OD): δ 8.41
(s, 1H), 8.17−8.06 (m, 1H), 8.01−7.88 (m, 2H), 7.72−7.63 (m, 1H),
7.55 (m, 3H), 6.26 (s, 2H), 5.52−5.31 (m, 2H + residual HDO), 3.37
(d, J = 20.6 Hz, 2H). 13C NMR (CD3OD): δ 139.1 (d, J = 6.8 Hz),
135.4, 132.4, 131.6, 130.15, 130.08, 129.7, 128.4, 128.1 (d, J = 5.0
Hz), 127.5, 126.6, 123.8, 55.1, 24.9 (d, J = 138.2 Hz). 31P NMR
(CD3OD): δ 21.6.
General Procedure for the Synthesis of Phosphonates via
Arbuzov Reaction. A stirred solution of the bromide (0.3 mmol) and
trimethylphosphite (2 mL, 17 mmol) was heated at 110 °C overnight.
Volatile materials were removed under vacuum, and the oily residue
was purified by flash column chromatography (DCM/MeOH) to give
the corresponding phosphonates.
Dimethyl {[1-(Naphthalen-1-yl)-1H-1,2,3-triazol-4-yl]methyl}-
phosphonate (10a). The compound is a colorless oil (78 mg,
82%). Rf = 0.24 (10% MeOH/EtOAc).
1H NMR (CDCl3): δ 8.05−
7.99 (m, 1H), 7.99−7.92 (m, 2H), 7.64−7.57 (m, 3H), 7.57−7.49
(m, 2H), 3.81 (d, J = 10.9 Hz, 6H), 3.50 (d, J = 20.5 Hz, 2H). 13C
NMR (CDCl3): δ 138.3 (d, J = 7.1 Hz), 134.3, 133.7, 130.6, 128.6,
128.4, 128.0, 127.2, 125.4 (d, J = 4.3 Hz), 125.1, 123.7, 122.4, 53.1 (d,
J = 6.7 Hz), 23.3 (d, J = 143.4 Hz). 31P NMR (CDCl3): δ 27.30.
Dimethyl (2-{1-[(Naphthalen-1-yl)methyl]-1H-1,2,3-triazol-4-yl}-
ethyl)phosphonate (10b). The compound is a colorless oil (95 mg,
92%). Rf = 0.67 (10% MeOH/DCM).
1H NMR (CDCl3): δ 8.13−
8.04 (m, 1H), 8.04−7.96 (m, 2H), 7.67−7.59 (m, 3H), 7.59−7.55
(m, 1H), 7.55−7.51 (m, 1H), 5.93 (s, 2H), 3.60 (d, J = 10.8 Hz, 6H),
3.01−2.79 (m, 2H), 2.19−1.99 (m, 2H). 13C NMR (CDCl3): δ
146.70 (d, J = 16.5 Hz), 134.0, 131.3, 130.09, 130.06, 129.0, 127.9,
127.3, 126.5, 125.4, 123.0, 121.0, 52.3 (d, J = 2.3 Hz), 24.3 (d, J =
141.2 Hz), 19.0 (d, J = 4.3 Hz). 31P NMR (CDCl3): δ 33.0.
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Dimethyl [(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]phosphonate
(19). The compound is a colorless oil (56 mg, 67%). Rf = 0.13 (5%
MeOH/DCM). 1H NMR (CDCl3): δ 7.52 (d, J = 2.4 Hz, 1H), 7.38−
7.32 (m, 3H), 7.30−7.23 (m, 2H), 5.51 (s, 2H), 3.71 (d, J = 10.9 Hz,
6H), 3.31 (d, J = 20.4 Hz, 2H). 13C NMR (CDCl3): δ 138.5 (d, J =
6.9 Hz), 134.7, 129.2, 128.8, 128.1, 122.7 (d, J = 4.3 Hz), 54.3, 53.1
(d, J = 6.7 Hz), 23.3 (d, J = 143.1 Hz). 31P NMR (CDCl3): δ 27.4.
Commercial Drugs. Acetylcholine (ACh) was purchased from
Sigma-Aldrich (St. Louis, MO, USA). Stock solution was prepared in
water.
Expression of Receptors. Receptors were transiently expressed in
BOSC23 cells, which are modified HEK293T cells. The receptors
were human α7 wild type (α7 WT, GenBank accession number
X70297); human α7 quintuple mutant (α7 TSLMF), which carries
five point mutations in the transmembrane domain (S223T, A226S,
M254L, I281M, and V288F) and is insensitive to the prototype type
II PAM PNU-120596;42 and the high-conductance form of the
chimeric receptor α7-5HT3A, which carries the sequence correspond-
ing to human α7 up to the beginning of the first transmembrane
domain and carries the sequence of the mouse serotonin type 3A
receptor (5-HT3A) thereafter.
5 Cells were transfected by calcium
phosphate precipitation with the subunit cDNA alone or together
with the chaperone Ric-3 cDNA (GenBank accession number
NM_024557.5) for α7 WT and α7 TSLMF.26,28 Ric-3 is an
endoplasmic-reticulum-resident protein that facilitates α7 subunit
folding and assembly into mature functional receptors on the cell
surface, allowing the heterologous expression of α7 receptors in
mammalian cells that do not endogenously express them.3,52 Green
fluorescence protein (GFP) cDNA (5% of total cDNA amount) was
incorporated during the transfection to allow identification of
transfected cells. All transfections were carried out for about 8−12
h in DMEM with 10% fetal bovine serum and were terminated by
exchanging the medium. Cells were used for whole-cell and single-
channel recordings 2−3 days after transfection at which time
maximum functional expression levels are usually achieved.25,26,28,29,42
Whole-Cell Recordings. Macroscopic currents were recorded in
the whole-cell configuration as described previously.25,26,29 The pipet
was filled with intracellular solution (ICS) containing 134 mM KCl, 5
mM EGTA, 1 mM MgCl2, and 10 mM HEPES (pH 7.3). The
extracellular solution (ECS) contained 150 mM NaCl, 1.8 mM CaCl2,
1 mM MgCl2, and 10 mM HEPES (pH 7.3). Agonist responses
(control currents) were obtained by a pulse of ECS containing the
agonist. The triazole derivatives were dissolved in ECS from DMSO
stock solutions. The final concentration of DMSO used to solubilize
the compounds was lower than 0.1% (v/v).
For testing compounds as PAMs of α7, macroscopic responses
were evaluated following a coapplication protocol. First, a 1.5 s pulse
of ECS containing ACh was applied (control current). Next, a second
pulse of ECS containing ACh and the compound was applied (treated
current). Finally, a pulse containing ACh alone in ECS was applied to
confirm recovery of the control current. This protocol was applied for
each cell, and the normalized treated currents were averaged for
different cells. The duration of the recording for all conditions was 2.0
s. The temporal parameters were selected considering the kinetics
characteristics of α7 macroscopic currents in BOSC23 cells.25,29 We
used a period of 8 s to washout the compound, because we verified
that this time allowed total recovery of control currents.
The solution exchange time was estimated by the open pipet and
varied between 0.1 and 1.0 ms.25,29 Currents were filtered at 5 kHz
and digitized at 20 kHz using an Axopatch 200B patch-clamp
amplifier (Molecular Devices, CA, USA), and they were acquired
using WinWCP software (Strathclyde Electrophysiology Software,
University of Strathclyde, Glasgow, UK). The recordings were
analyzed using the ClampFit software (Molecular Devices, CA,
USA). Each current represents the average from three to five
individual traces obtained from the same cell, which were aligned with
each other at the maximum peak. Currents were fitted by a double
exponential function according to the equation:
τ τ= [ − ] + [ − ] + ∞I t I t I t I( ) exp ( / ) exp ( / )fast fast slow slow
in which t is time, Ifast and Islow are the peak current values, I∞ is the
steady state current value, and τfast and τslow are the fast and slow
decay time constants, respectively. Net charge was calculated by
current integration.25,29
Single-Channel Recordings. Single-channel recordings were
obtained in the cell-attached patch configuration.26 Each patch
corresponded to a different cell (n indicates the number of
independent experiments). For each condition (distinct receptors or
drugs), three or more different cell transfections from distinct days
were performed for the recordings (N indicates the number of cell
transfections). The bath and pipet solutions contained 142 mM KCl,
5.4 mM NaCl, 1.8 mM CaCl2, 1.7 mM MgCl2, and 10 mM HEPES
(pH 7.4). Only for the chimeric receptor α7-5HT3A, the bath and
pipet solutions were free of Mg2+ and had a low calcium concentration
(0.2 mM CaCl2), in order to minimize channel block by divalent
cations as previously described.25,29,37
For testing the effect of the different triazole derivatives on α7 WT,
each compound was added to the pipet solution with ACh. Thus,
single channels were recorded in the continuous presence of the
drugs. Typical recordings lasted between 5 and 10 min. The final
concentration of DMSO used to solubilize the compounds was lower
than 0.1% (v/v), which does not affect α7 activation properties.25,29
ACh was solubilized directly in the pipet solution.27 Single-channel
currents were digitized at 5−10 μs intervals, low-pass filtered at a
cutoff frequency of 10 kHz using an Axopatch 200B patch-clamp
amplifier (Molecular Devices, CA, USA), and analyzed using the
program TAC (Bruxton Corporation, Seattle, WA, USA) with the
Gaussian digital filter at 9 kHz (final cutoff frequency 6.7 kHz).
Events were detected by the half amplitude threshold criterion.5 To
define amplitude classes, analysis was performed by tracking events
regardless of current amplitude. Amplitude histograms were then
constructed to determine single-channel amplitude. Open time
histograms were fitted by the sum of exponential functions by
maximum likelihood using the program TACFit (Bruxton Corpo-
ration, Seattle, WA, USA). Bursts of channel openings were identified
as a series of closely separated openings preceded and followed by
closings longer than a critical duration (τcrit), which was taken as the
point of intersection between closed components as described
before.25−29 Thus, each series of opening events spaced by durations
briefer than τcrit was grouped to form a single burst. Burst duration
was determined from the longest duration component of the open
time histogram constructed with an imposed τcrit. The briefest
components of the burst duration histograms correspond to isolated
openings.
Critical durations were defined by the intersection between the first
and second briefest components in the closed time histogram for
bursts of α7 (∼200−400 μs) and the second and third closed
components for bursts of α7 TSLMF (∼1−4 ms) and α7-5HT3A
(∼2−5 ms), activated by ACh. In the presence of potentiators, the
critical time was defined between the second and the third closed
components for bursts of α7 (∼1−5 ms). For α7 TSLMF and α7-
5HT3A, the critical times did not show differences in the absence or
presence of triazole derivatives together with ACh.
The closed components corresponding to interburst closings were
not analyzed because of their intrinsic variability, which depends on
the expression level of α7 in each cell. Also, intraburst closings were
not analyzed, because they cannot provide reliable kinetic information
due to their very brief duration and low frequency in control
recordings.
Statistical Analysis. Data were presented as mean ± SD. Data sets
that passed the Shapiro−Wilk test for normality and the Levene
Median test for equal variance were analyzed using the two-tailed
Student’s t-test for pairwise comparisons or one way ANOVA
followed by Bonferroni’s post hoc tests for multiple comparisons. All
the tests were performed with SigmaPlot 12.0 (Systat Software, Inc.).
A statistically significant difference was established at p-values < 0.05
(p < 0.05*, p < 0.01**, p < 0.001***).
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M. G. (2015) Anti-Inflammatory Role of Microglial Alpha7 nAChRs
and Its Role in Neuroprotection. Biochem. Pharmacol. 97 (4), 463−
472.
(5) Bouzat, C., Gumilar, F., Spitzmaul, G., Wang, H. L., Rayes, D.,
Hansen, S. B., Taylor, P., and Sine, S. M. (2004) Coupling of Agonist
Binding to Channel Gating in an ACh-Binding Protein Linked to an
Ion Channel. Nature 430 (7002), 896−900.
(6) Dajas-Bailador, F., and Wonnacott, S. (2004) Nicotinic
Acetylcholine Receptors and the Regulation of Neuronal Signalling.
Trends Pharmacol. Sci. 25 (6), 317−324.
(7) Thomsen, M. S., Hansen, H. H., Timmerman, D. B., and
Mikkelsen, J. D. (2010) Cognitive Improvement by Activation of α7
Nicotinic Acetylcholine Receptors: From Animal Models to Human
Pathophysiology. Curr. Pharm. Des. 16 (3), 323−343.
(8) Chatzidaki, A., and Millar, N. S. (2015) Allosteric Modulation of
Nicotinic Acetylcholine Receptors. Biochem. Pharmacol. 97 (4), 408−
417.
(9) Yang, T., Xiao, T., Sun, Q., and Wang, K. (2017) The Current
Agonists and Positive Allosteric Modulators of α7 nAChR for CNS
Indications in Clinical Trials. Acta Pharm. Sin. B 7 (6), 611−622.
(10) Grønlien, J. H., Håkerud, M., Ween, H., Thorin-Hagene, K.,
Briggs, C. A., Gopalakrishnan, M., and Malysz, J. (2007) Distinct
Profiles of α7 nAChR Positive Allosteric Modulation Revealed by
Structurally Diverse Chemotypes. Mol. Pharmacol. 72 (3), 715−724.
(11) Faghih, R., Gopalakrishnan, M., and Briggs, C. A. (2008)
Allosteric Modulators of the α7 Nicotinic Acetylcholine Receptor. J.
Med. Chem. 51 (4), 701−712.
(12) Chatzidaki, A., D'Oyley, J. M., Gill-Thind, J. K., Sheppard, T.
D., and Millar, N. S. (2015) The Influence of Allosteric Modulators
and Transmembrane Mutations on Desensitisation and Activation of
α7 Nicotinic Acetylcholine Receptors. Neuropharmacology 97, 75−85.
(13) Newcombe, J., Chatzidaki, A., Sheppard, T. D., Topf, M., and
Millar, N. S. (2018) Diversity of Nicotinic Acetylcholine Receptor
Positive Allosteric Modulators Revealed by Mutagenesis and a
Revised Structural Model. Mol. Pharmacol. 93 (2), 128−140.
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://dx.doi.org/10.1021/acschemneuro.0c00348
ACS Chem. Neurosci. 2020, 11, 2688−2704
2702
(14) Dheer, D., Singh, V., and Shankar, R. (2017) Medicinal
Attributes of 1,2,3-Triazoles: Current Developments. Bioorg. Chem.
71, 30−54.
(15) Bozorov, K., Zhao, J., and Aisa, H. A. (2019) 1,2,3-Triazole-
Containing Hybrids as Leads in Medicinal Chemistry: A Recent
Overview. Bioorg. Med. Chem. 27 (16), 3511−3531.
(16) Massarotti, A., Aprile, S., Mercalli, V., Del Grosso, E., Grosa, G.,
Sorba, G., and Tron, G. C. (2014) Are 1,4-and 1,5-Disubstituted
1,2,3-Triazoles Good Pharmacophoric Groups? ChemMedChem 9
(11), 2497−2508.
(17) Alonso, F., Moglie, Y., Radivoy, G., and Yus, M. (2010)
Multicomponent Synthesis of 1,2,3-Triazoles in Water Catalyzed by
Copper Nanoparticles on Activated Carbon. Adv. Synth. Catal. 352
(18), 3208−3214.
(18) Alonso, F., Moglie, Y., Radivoy, G., and Yus, M. (2011) Click
Chemistry from Organic Halides, Diazonium Salts and Anilines in
Water Catalysed by Copper Nanoparticles on Activated Carbon. Org.
Biomol. Chem. 9 (18), 6385−6395.
(19) Petkowski, J., Bains, W., and Seager, S. (2019) Natural Products
Containing ‘Rare’ Organophosphorus Functional Groups. Molecules
24 (5), 1−66.
(20) Horsman, G. P., and Zechel, D. L. (2017) Phosphonate
Biochemistry. Chem. Rev. 117 (8), 5704−5783.
(21) Bonandi, E., Christodoulou, M. S., Fumagalli, G., Perdicchia,
D., Rastelli, G., and Passarella, D. (2017) The 1,2,3-Triazole Ring as a
Bioisostere in Medicinal Chemistry. Drug Discovery Today 22 (10),
1572−1581.
(22) de Lourdes G. Ferreira, M., Pinheiro, L. C. S., Santos-Filho, O.
A., Pecanha, M. D. S., Sacramento, C. Q., Machado, V., Ferreira, V. F.,
Souza, T. M. L., and Boechat, N. (2014) Design, Synthesis, and
Antiviral Activity of New 1H-1,2,3-Triazole Nucleoside Ribavirin
Analogs. Med. Chem. Res. 23 (3), 1501−1511.
(23) Yermolina, M. V., Wang, J., Caffrey, M., Rong, L. L., and
Wardrop, D. J. (2011) Discovery, Synthesis, and Biological Evaluation
of a Novel Group of Selective Inhibitors of Filoviral Entry. J. Med.
Chem. 54 (3), 765−781.
(24) Dinklo, T., Shaban, H., Thuring, J. W., Lavreysen, H., Stevens,
K. E., Zheng, L., Mackie, C., Grantham, C., Vandenberk, I., Meulders,
G., Peeters, L., Verachtert, H., De Prins, E., and Lesage, A. S. J. (2011)
Characterization of 2-[[4-Fluoro-3-(Trifluoromethyl)Phenyl]Amino]-
4-(4-Pyridinyl)-5-Thiazolemethanol (JNJ-1930942), a Novel Positive
Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor. J.
Pharmacol. Exp. Ther. 336 (2), 560−574.
(25) Nielsen, B. E., Bermudez, I., and Bouzat, C. (2019) Flavonoids
as Positive Allosteric Modulators of α7 Nicotinic Receptors.
Neuropharmacology 160, 107794.
(26) Bouzat, C., Bartos, M., Corradi, J., and Sine, S. M. (2008) The
Interface between Extracellular and Transmembrane Domains of
Homomeric Cys-Loop Receptors Governs Open-Channel Lifetime
and Rate of Desensitization. J. Neurosci. 28 (31), 7808−7819.
(27) Andersen, N., Corradi, J., Sine, S. M., and Bouzat, C. (2013)
Stoichiometry for Activation of Neuronal α7 Nicotinic Receptors.
Proc. Natl. Acad. Sci. U. S. A. 110 (51), 20819−20824.
(28) Nielsen, B. E., Minguez, T., Bermudez, I., and Bouzat, C.
(2018) Molecular Function of the Novel α7β2 Nicotinic Receptor.
Cell. Mol. Life Sci. 75 (13), 2457−2471.
(29) Andersen, N., Nielsen, B. E., Corradi, J., Tolosa, M. F.,
Feuerbach, D., Arias, H. R., and Bouzat, C. (2016) Exploring the
Positive Allosteric Modulation of Human α7 Nicotinic Receptors
from a Single-Channel Perspective. Neuropharmacology 107, 189−
200.
(30) Fabiani, C., Murray, A. P., Corradi, J., and Antollini, S. S.
(2018) A Novel Pharmacological Activity of Caffeine in the
Cholinergic System. Neuropharmacology 135, 464−473.
(31) Zwart, R., Van Kleef, R. G. D. M., Gotti, C., Smulders, C. J. G.
M., and Vijverberg, H. P. M. (2000) Competitive Potentiation of
Acetylcholine Effects on Neuronal Nicotinic Receptors by Acetylcho-
linesterase-Inhibiting Drugs. J. Neurochem. 75 (6), 2492−2500.
(32) Pereira, E. F. R., Hilmas, C., Santos, M. D., Alkondon, M.,
Maelicke, A., and Albuquerque, E. X. (2002) Unconventional Ligands
and Modulators of Nicotinic Receptors. J. Neurobiol. 53 (4), 479−
500.
(33) Gill-Thind, J. K., Dhankher, P., D'Oyley, J. M., Sheppard, T. D.,
and Millar, N. S. (2015) Structurally Similar Allosteric Modulators of
α7 Nicotinic Acetylcholine Receptors Exhibit Five Distinct
Pharmacological Effects. J. Biol. Chem. 290 (6), 3552−3562.
(34) Liu, H., Wang, L., Lv, M., Pei, R., Li, P., Pei, Z., Wang, Y., Su,
W., and Xie, X. (2014) AlzPlatform: An Alzheimer’s Disease Domain-
Specific Chemogenomics Knowledgebase for Polypharmacology and
Target Identification Research. J. Chem. Inf. Model. 54 (4), 1050−
1060.
(35) Pardridge, W. M. (2005) The Blood-Brain Barrier: Bottleneck
in Brain Drug Development. NeuroRx 2 (1), 3−14.
(36) Daina, A., and Zoete, V. (2016) A BOILED-Egg To Predict
Gastrointestinal Absorption and Brain Penetration of Small
Molecules. ChemMedChem 11 (11), 1117−1121.
(37) Rayes, D., Spitzmaul, G., Sine, S. M., and Bouzat, C. (2005)
Single-Channel Kinetic Analysis of Chimeric α7−5HT3A Receptors.
Mol. Pharmacol. 68 (5), 1475−1483.
(38) Galzi, J. L., Bertrand, S., Corringer, P.-J., Changeux, J.-P., and
Bertrand, D. (1996) Identification of Calcium Binding Sites That
Regulate Potentiation of a Neuronal Nicotinic Acetylcholine
Receptor. EMBO J. 15 (21), 5824−5832.
(39) Lee, B.-H., Choi, S.-H., Shin, T.-J., Pyo, M. K., Hwang, S.-H.,
Kim, B.-R., Lee, S.-M., Lee, J.-H., Kim, H.-C., Park, H.-Y., Rhim, H.,
and Nah, S.-Y. (2010) Quercetin Enhances Human α7 Nicotinic
Acetylcholine Receptor-Mediated Ion Current through Interactions
with Ca2+ Binding Sites. Mol. Cells 30 (3), 245−253.
(40) Grønlien, J. H., Ween, H., Thorin-Hagene, K., Cassar, S., Li, J.,
Briggs, C. A., Gopalakrishnan, M., and Malysz, J. (2010) Importance
of M2−M3 Loop in Governing Properties of Genistein at the α7
Nicotinic Acetylcholine Receptor Inferred from A7/5-HT3A
Chimera. Eur. J. Pharmacol. 647 (1−3), 37−47.
(41) Young, G. T., Zwart, R., Walker, A. S., Sher, E., and Millar, N. S.
(2008) Potentiation of α7 Nicotinic Acetylcholine Receptors via an
Allosteric Transmembrane Site. Proc. Natl. Acad. Sci. U. S. A. 105
(38), 14686−14691.
(42) DaCosta, C. J. B., Free, C. R., Corradi, J., Bouzat, C., and Sine,
S. M. (2011) Single-Channel and Structural Foundations of Neuronal
α7 Acetylcholine Receptor Potentiation. J. Neurosci. 31 (39), 13870−
13879.
(43) Collins, T., Young, G. T., and Millar, N. S. (2011) Competitive
Binding at a Nicotinic Receptor Transmembrane Site of Two α7-
Selective Positive Allosteric Modulators with Differing Effects on
Agonist-Evoked Desensitization. Neuropharmacology 61 (8), 1306−
1313.
(44) Collins, T., and Millar, N. S. (2010) Nicotinic Acetylcholine
Receptor Transmembrane Mutations Convert Ivermectin from a
Positive to a Negative Allosteric Modulator. Mol. Pharmacol. 78 (2),
198−204.
(45) Timmermann, D. B., Grønlien, J. H., Kohlhaas, K. L., Nielsen,
E. O., Dam, E., Jorgensen, T. D., Ahring, P. K., Peters, D., Holst, D.,
Chrsitensen, J. K., Malysz, J., Briggs, C. A., Gopalakrishnan, M., and
Olsen, G. M. (2007) An Allosteric Modulator of the α7 Nicotinic
Acetylcholine Receptor Possessing Cognition-Enhancing Properties in
Vivo. J. Pharmacol. Exp. Ther. 323 (1), 294−307.
(46) Hurst, R. S., Hajos, M., Raggenbass, M., Wall, T. M., Higdon,
N. R., Lawson, J. A., Rutherford-Root, K. L., Berkenpas, M. B.,
Hoffmann, W. E., Piotrowski, D. W., Groppi, V. E., Allaman, G.,
Ogier, R., Bertrand, S., Bertrand, D., and Arneric, S. P. (2005) A
Novel Positive Allosteric Modulator of the α7 Neuronal Nicotinic
Acetylcholine Receptor: In Vitro and In Vivo Characterization. J.
Neurosci. 25 (17), 4396−4405.
(47) Dutta, S., Gupta, S. J., and Sen, A. K. (2016) Silver
Trifluoromethanesulfonate and Metallic Copper Mediated Syntheses
of 1,2,3-Triazole-O- and Triazolyl Glycoconjugates: Consecutive
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://dx.doi.org/10.1021/acschemneuro.0c00348
ACS Chem. Neurosci. 2020, 11, 2688−2704
2703
Glycosylation and Cyclization under One-Pot Condition. Tetrahedron
Lett. 57 (29), 3086−3090.
(48) Jin, Y., Zhu, J., Zhang, Z., Cheng, Z., Zhang, W., and Zhu, X.
(2008) Synthesis and Characterizations of 1,2,3-Triazole Containing
Polymers via Reversible Addition-Fragmentation Chain Transfer
(RAFT) Polymerization. Eur. Polym. J. 44 (6), 1743−1751.
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